EP3893846B1 - Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols - Google Patents

Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols Download PDF

Info

Publication number
EP3893846B1
EP3893846B1 EP19821400.9A EP19821400A EP3893846B1 EP 3893846 B1 EP3893846 B1 EP 3893846B1 EP 19821400 A EP19821400 A EP 19821400A EP 3893846 B1 EP3893846 B1 EP 3893846B1
Authority
EP
European Patent Office
Prior art keywords
composition
herbicides
insecticides
polyalkoxylated
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19821400.9A
Other languages
German (de)
French (fr)
Other versions
EP3893846A1 (en
Inventor
Michael P. Tate
Thomas H. Kalantar
Michael L. Tulchinsky
David Brennan
Adam H. XIONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Global Technologies LLC
Original Assignee
Dow Global Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies LLC filed Critical Dow Global Technologies LLC
Publication of EP3893846A1 publication Critical patent/EP3893846A1/en
Application granted granted Critical
Publication of EP3893846B1 publication Critical patent/EP3893846B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647Triazoles; Hydrogenated triazoles
    • A01N43/6531,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/20N-Aryl derivatives thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01PBIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00Fungicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Definitions

  • the field of this invention is aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols.
  • aqueous solution It is often desirable to utilize certain types of active materials in aqueous solution. For example, it can be desirable to have and dispense certain pharmaceuticals in aqueous solution. As another example, it can be desirable to dispense agricultural chemicals such as pesticides and herbicides in a spray on aqueous solution. However, some of these materials are not soluble at the concentrations which provide effective dosages.
  • WO2014/080190 discloses an agrochemical formulation comprising an agrochemical active and an esterified or etherified polyol alkoxylate as a penetrant.
  • US2012/021914 discloses suspension concentrates of a plant protective agent comprising alcohol alkylate and cyclodextrin.
  • WO01/94001 discloses microcapsules having an encapsulated material therein where the shell comprises a polymer having a surface modifying compound capable of reacting with isocyanate.
  • US2008/312290 discloses an oil based suspension concentrate of solid agrochemical active substance.
  • US2015/374823 discloses alkoxylated alcohols having the formula R-O-(AO)-H as excipient in pharmaceutical compositions.
  • JP2009-108176 discloses a thickener composition for a liquid detergent comprising at least one of a non-ionic surfactant A and a nonionic surfactant B in the molar ratios of A:B of 100:0 to 80:20.
  • US2016/289590 discloses a composition for use as a lubricant in a mechanical device, which composition comprises a base oil and a dispersant, the base oil comprising a polyalkylene glycol and the dispersant being an epoxy amine alkoxylate.
  • compositions comprising a biologically active compound that is insoluble or poorly soluble in water and a polyalkoxylated amino alcohol of the formula where R 1 , R 2 , R 3 , and R 4 are independently selected from alkyl, alkenyl, aryl, aralkyl, or heterocyclic groups having 1 - 25 carbons, R 5 is a divalent alkyl, alkenyl, aryl, aralkyl, or heterocyclic group having 4-25 carbons, and where each AO is a polyoxyalkylene chain having oxypropylene (PO) groups and oxyethylene (EO) groups, where m is the average number of PO groups per AO group and n is the average number of EO groups per AO group, and m is at least 1, n is at least 2, and m+n is at least 20 and
  • R 1 , R 2 , R 3 , and R 4 are independently selected from alkyl, alkenyl, aryl, aralkyl, or heterocyclic groups
  • Biologically active compounds are compounds which have a negative or positive impact on a living organism by interacting chemically with a living organism.
  • Biologically active compounds include pharmaceutical actives (also referred to as active pharmaceutical ingredients or APIs) which are any substance for application in a therapeutic, diagnostic or prophylactic medical treatment of the human or animal body and (e.g.
  • active ingredients used for these purposes include fungicides, bactericides, herbicides, insecticides, miticides, algaecides, nematocides and fumigants.
  • active ingredient also includes insect repellants and attractants and pheromones, modifiers of plant physiology or structure, zoospore attractants and herbicide safeners.
  • biologically active compounds are considered poorly soluble if they precipitate or crystallize at concentrations at which the use is desired. For example, if a compound is most useful at concentrations or dosages of 50 mg/L but significant precipitation occurs at 20 mg/L that compound would be considered poorly soluble.
  • the biologically active compound can have a solubility in water or aqueous medium of up to 1000, up to 700, up to 500, up to 300, up to 200, up to 100, up to 50, up to 40, up to 30, up to 20 or up to 10 parts per million.
  • the biologically active compound can have a solubility in aqueous medium or water of up to 50, or up to 20 or up to 10 or up to 1 mg/L.
  • the solubility of the biological active in an aqueous medium can be determined quantitatively e.g. by turbidity as shown in the examples below or by high pressure liquid chromatography.
  • a solid biological active (potentially with solid excipients) is placed in an aqueous medium, after stirring for a period of time a sample would be injected into an HPLC system with an appropriate column and the area at the expected retention time based on a control sample of the active at a known concentration is evaluated.
  • the polyalkoxylated amino alcohol has the formula where R 1 , R 2 , R 3 , and R 4 can be independently selected from alkyls of from 1 or from 2 or from 3 or from 4 to 25 or to 15 to 13 or to 12 or to 10 carbon atoms, alkenyls of from 2 or from 3 or from 4 to 25 or to 15 or to 13 or to 12 to 10 carbon atoms, aryls of 6 to 24 or to 12 carbon atoms, aralkyls of 7 to 25 or to 12 carbon atoms, or heterocyclic groups having 1 - 25 carbons, R 5 can be a divalent alkyl from 4 to 25 or to 15 to 13 or to 12 or to 10 carbon atoms, alkenyl from 4 to 25 or to 15 to 13 or to 12 or to 10 carbon atoms, aryl of 6 to 24 or to 12 carbon atoms, aralkyl 7 to 25 or to 12 carbon atoms, or heterocyclic group having 4-25 carbons, and where each AO is a polyoxyal
  • R 1 , R 2 , R 3 , and R 4 can be independently in each occurrence alkyl groups.
  • R 1 , R 2 , R 3 , and R 4 can be butyl or ethylhexyl groups.
  • R 1 , R 2 , R 3 , and R 4 can be independently in each occurrence aryl groups, aralkyl groups.
  • R 5 can be a divalent group comprising 1 or 2 aromatic rings such as a diphenyl, diphenylmethane, diphenylethane, or the like and having from 6 to 25 or to 20 or to 18 carbon atoms (i.e., 6-25 or 6-20 or 6-18 carbon atoms).
  • R 5 with the adjacent oxygens can be derivative of bisphenol A.
  • R 5 can be an aliphatic group having linear groups or cyclic groups or a combination of linear and cyclic groups and having from 3 or from 4 to 20 or to 18 or to 15 carbon atoms.
  • R 5 can be 2,2-isopropylidenediphenylene, 2,2-isopropylidenedicyclohexylidene or 1,4-butylene.
  • the AO can be blocky in that it can have an EO rich block and a PO rich block.
  • EO rich block is meant that more than 50, more than 55, more than 60, more than 65, more than 70, more than 75, more than 80, more than 85, more than 90 or more than 95% of the groups in the block are EO groups.
  • EO rich blocks are helpful in ensuring good water solubility.
  • PO rich block is meant that more than 50, more than 55, more than 60, more than 65, more than 70, more than 75, more than 80, more than 85, more than 90 or more than 95 of the groups in the block are PO groups.
  • the AO group can be a block copolymer having separate EO blocks and PO blocks.
  • m and n e.g. by NMR
  • the minimum value of m can be 1, 2, 3, 4, 5, 7, 10, 12, 15, 18 or 20.
  • the maximum value of m can be 100, 90, 80, 70, 60, or 50.
  • m could be from 1 to 100, 1 to 90, or 5 to 90.
  • the minimum value of n can be 2, 3, 4, 5, 10, 15, 20, 25, 30, or 40.
  • the maximum value of n can be 150, 130, 110, 100, 90, 80, or 70.
  • m/n is preferably ⁇ 1.
  • m+n has a minimum value of 20, and can have a minimum value of 30, 40 or 50;
  • m+n has a maximum value of 400, and can have a maximum value of 350, 300, 250, 200, or 150.
  • the biological active (e.g. agricultural active) and polyalkoxylated amino alcohol can be present in weight ratios in the range from 10:1 or from 5:1 or from 1: 1or from 1:2 to 1:100, or to 1:50, or to 1:20, or to 1:10, or to 1:5.
  • the mole ratio of biological active to polyalkoxylated amino alcohol can be from 1:1 or from 1:2 to 1:20 or to 1:10.
  • the composition can be a liquid comprising the biological active and the polyalkoxylated amino alcohol in an aqueous medium.
  • concentration of the combination of the biological active and the polyalkoxylated amino alcohol is at least 10 or at least 50 or at least 100 or at least 200 parts per million (ppm) by weight and is no more than 10 or no more than 5 or no more than 1 parts per hundred (pph) by weight.
  • the use of the polyalkoxylated amino alcohol can assist in the use of poorly water soluble agricultural active ingredients, for example, in spray applications on agricultural fields, orchards or the like.
  • the use of the polyalkoxylated amino alcohol can inhibit flash precipitation that would occur if a solvent based formulation is diluted with water or can enhance solubility of solid actives.
  • the use of the polyalkoxylated amino alcohol may provide one or more of the following benefits, for example, 1) extended stability of aqueous agricultural active systems compared to systems that do not contain the polyalkoxylated amino alcohols; 2) produce a controlled precipitation of the agricultural active ingredient generating a controlled fine particle size distribution; 3) produce finer agricultural active ingredient particles, droplets, or precipitates in aqueous systems that do not plug nozzles and present slower settling rates compared to systems that do not contain the polyalkoxylated amino alcohols; and/or 4) hinder and/or delay the formation of large precipitates that generate problems for spray applications.
  • the enhanced solubility could enhance efficacy if for example the mode of action includes uptake of the agricultural active ingredient by the plant or animal which uptake is enhanced by higher concentration of the active in solution or if more uniform distribution is required than is attainable by particulates.
  • insecticides include antibiotic insecticides such as allosamidin and thuringensin, macrocyclic lactone insecticides such as spinosad, spinetoram and 21-butenyl spinosyns; avermectin insecticides such as abamectin, doramectin, emamectin, eprinomectin, ivermectin and selamectin; milbemycin insecticides such as lepimectin, milbemectin, milbemycin oxime and moxidectin; botanical insecticides such as anabasine, azadirachtin, d-limonene, nicotine, pyrethrins, cinerins, cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II, quassia, rotenone, ryania and sabadilla; carbamate
  • fungicides include ametoctradin, amisulbrom 2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol, 8-hydroxyquinoline sulfate, antimycin, azaconazole, azoxystrobin, benalaxyl, benomyl, benthiavalicarb-isopropyl, benzylaminobenzene-sulfonate (BABS) salt, bicarbonates, biphenyl, bismerthiazol, bitertanol, bixafen, blasticidin-S, borax, Bordeaux mixture, boscalid, bromuconazole, bupirimate, BYF 1047, calcium polysulfide, captafol, captan, carbendazim, carboxin, carpropamid, carvone, chloroneb, chlorothalonil, chlozolinate, copper hydroxide, copper octanoate, copper oxychloride
  • herbicides include amide herbicides such as allidochlor, beflubutamid, benzadox, benzipram, bromobutide, cafenstrole, CDEA, chlorthiamid, cyprazole, dimethenamid, dimethenamid-P, diphenamid, epronaz, etnipromid, fentrazamide, flupoxam, fomesafen, halosafen, isocarbamid, isoxaben, napropamide, naptalam, pethoxamid, propyzamide, quinonamid and tebutam; anilide herbicides such as chloranocryl, cisanilide, clomeprop, cypromid, diflufenican, etobenzanid, fenasulam, flufenacet, flufenican, mefenacet, mefluidide, metamifop, monalide, napro
  • modifiers of plant physiology or structure include ancymidol, aminoethoxyvinylglycine, 6-benzylaminopurine, carvone, chlorflurenol-methyl, chlormequat chloride, cloxyfonac, 4-CPA, cyclanilide, cytokinins, daminozide, dikegulac, ethephon, flurenol, flurprimidol, forchlorfenuron, gibberellic acids, gibberellins, inabenfide, indol-3-ylacetic acid, 4-indol-3ylbutyric acid, maleic hydrazide, mepiquat chloride, 1-methylcyclopropene, 2-(l-napthyl)acetamide, 1-napthylacetic acid, 2-napthyloxyacetic acid, nitrophenolates, paclobutrazol, Nphenylphthalamic acid, prohexadione-calcium, n-propyl
  • herbicide safeners examples include safeners such as benoxacor, benthiocarb, brassinolide, cloquintocet (mexyl), cyometrinil, cyprosulfamide, daimuron, dichlormid, dicyclonon, dimepiperate, disulfoton, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, MG 191, MON 4660, naphthalic anhydride (NA), oxabetrinil, R29148 and N-phenylsulfonylbenzoic acid amides.
  • safeners such as benoxacor, benthiocarb, brassinolide, cloquintocet (mexyl), cyometrinil, cyprosulfamide, daimuron, dichlormid, di
  • the formulation may also comprise a water miscible solvent or a solvent that is soluble in water in amounts of from 0.5 or from 1 or from 2 or from 3 or from 4 or from 5 or from 10 weight percent up to 30 or up to 20 weight percent based on total weight of water and solvent.
  • solvents include glycol ethers, alcohols and ketones and they are miscible or soluble depending upon the size of the hydrocarbyl groups.
  • Water miscible solvents include N-Methyl-2-pyrrolidone, ethylene glycol monobutyl ether, ethyl lactate, gamma-butyrolactone, propylene glycol, propylene glycol methyl ether, tetrahydrofurfuryl alcohol, 2-ethoxyethanol, dimethyl sulfoxide, 1-methoxy-2-propanol, 2-butoxyethanol, dipropylene glycol methyl ether, n-propanol, and acetone.
  • Water soluble solvents include acetophenone, butyl lactate, cyclohexanone, propylene carbonate, methyl isobutyl ketone, n-butanol, ethylene glycol n-butyl acetate, ethylene glycol phenyl ether.
  • Applications that are "in-can" applications frequently include such a solvent.
  • This formulation may further include water or may be diluted with water prior to application to the intended area where herbicidal or pesticidal protection is desired. Without the presence of the polyalkoxylated amino alcohol, the dilution with water might cause the poorly soluble active to precipitate.
  • the weight ratio of solvent to water can be at least 0.1:99.9 or at least 1:99 or at least 5:95 or at least 10:90 and is no more than 99:1 or no more than 90:10 or no more than 80:20 or no more than 70:30 or no more than 60:40 or no more than 50:50.
  • the formulation could alternatively be in solid particles which are added to a tank with water prior to application to the location where the herbicide or pesticide protection is desired (e.g. field or warehouse).
  • This embodiment could be formed by mixing the polyalkoxylated amino alcohol and pesticide together such as by dissolving in a common solvent and removing that solvent, or by spray drying together, or other such means to make a solid or semi-solid composition that can be diluted in a tank for application to a crop or field.
  • the aqueous solution including the active and the polyalkoxylated amino alcohol can be applied by spraying.
  • ingredients in an agricultural active containing formulation may be inactive or inert ingredients such as dispersants, thickening agents, stickers, filmforming agents, buffers, emulsifiers, anti-freezing agents, dyes, stabilizers, solid carriers and the like may also be incorporated into formulations.
  • Those additional ingredients can be present, individually and/or cumulatively in amounts of less than 10 or less than 8 or less than 5 or less than 3 or less than 2 or less than 1 weight percent and 0 weight percent or at least 0.1 or at least 0.5 based on total weight of the composition.
  • the use of the polyalkoxylyated amino alcohols can enable solubilization of poorly water soluble active pharmaceutical ingredients to enhance processability in manufacture of tablets and the like (e.g. by spray drying).
  • poor aqueous solubility of pharmaceutical actives also referred to as active pharmaceutical ingredients or APIs
  • the active pharmaceutical ingredient can generally be any substance for application in a therapeutic, diagnostic or prophylactic medical treatment of the human or animal body.
  • the API may for instance be selected from the group of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose lowering agents, decongestants, antihistamines, antitussives, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, cholesterol-reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial agents, antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, anti-depressants, antiviral agents, anti-atherosclerotic agents, glycogen phosphorylase inhibitors, hormones, vitamins, carotinoids, antiseptic agents, cytostatics, anesthetics, neuroleptics, antimycotics, spasmolytic agents, immunoglobines, sera, thyroid therapeutic agents,
  • the use of the polyalkoxylated amino alcohols may be particularly useful for APIs which are poorly soluble in aqueous medium such as a class II drug according to the Biopharmaceutics Classification System (BCS) as these substances typically suffer from an insufficient bioavailability.
  • aqueous medium such as a class II drug according to the Biopharmaceutics Classification System (BCS) as these substances typically suffer from an insufficient bioavailability.
  • BCS Biopharmaceutics Classification System
  • the pharmaceutical composition can comprise further one or more physiologically compatible additives.
  • Any conventional additives used in pharmaceutical compositions known from the prior art can be employed as long as they do not interfere with the action of the active pharmaceutical ingredient and do not adversely affect the above-described favorable effects imparted by the polyalkoxylated alcohol.
  • the at least one optional additive may for instance be selected from the group of fillers, pH regulators, solvents, surfactants, antioxidants, preservative agents, plasticizers, coloring agents, flavoring agents, mineral adjuvants, emollients, lubricants, perfumes and excipients other than the polyalkoxylated alcohols according to the present invention and mixtures of any of the foregoing.
  • Suitable antioxidants can be exemplified by ascorbic acid, citric acid, vitamin E and derivatives of these compounds, as well as butylated hydroxyanisole.
  • plasticizer for instance mineral oils, petrolatum, lanolin, polyethylene glycol, polypropylene glycol, sorbitol, triethanol amine, benzyl benzoate, dibutyl sebacate, diethyl phthalate, glyceryl monostearate, triacetin and/or triethyl citrate could be used.
  • Suitable solvents are e.g. water, alcohols such as ethanol, isopropyl alcohol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol and glycerol.
  • Eligible pH regulators can be all types of physiologically acceptable acids and/or bases.
  • Suitable surfactants can be nonionic, cationic, anionic or of the betain type.
  • Fillers that may be incorporated in the pharmaceutical composition of the present invention e.g. to modify the consistency or appearance include, without being limited thereto, for instance pigments, titania, alumina, silica, zinc oxide, magnesium stearate, silicates, alumosilicates, clay, talc, waxes and polymers e.g. cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl-cellulose.
  • Excipients other than the polyalkoxylated alcohols according to the present invention can be exemplified for instance by the substances mentioned as excipients in the Handbook of Pharmaceutical Excipients, Third Edition, Edited by A. H. Kibbe, American Pharmaceutical Association and Pharmaceutical Press (2000 ), WO 00/76482 and Tables 3-5 in E. T. Cole et al., Advanced Drug Delivery Reviews 60 (2008), 747-756 .
  • the composition can comprise the at least one active pharmaceutical ingredient and the at least one polyalkoxylated amino alcohol together in a combined amount corresponding to 1 to 100 wt. %, preferably at least 10 wt. %, more preferably at least 50 wt. % based on the total weight of the composition.
  • the remainder of the pharmaceutical composition may then comprise physiologically compatible additives, if any.
  • Such additives may thus e.g. comprise 0 to 99 wt. %, preferably 0 to 90 wt. % or 0 to 50 wt. % based on the total weight of the pharmaceutical composition.
  • the relative amount of the at least one active pharmaceutical ingredient and the at least one polyalkoxylated alcohol can be in a weight ratio in the range from 10:1 to 1:100 of active pharmaceutical ingredient(s):the polyalkoxylated alcohol, preferably from 5:1 to 1:10, more preferably from 1: 1 to 1:3.
  • the at least one polyalkoxylated alcohol can be present in the pharmaceutical composition in an amount of more than 5 wt. %, preferably at least 10 wt. %, more preferably at least 25 wt. %, most preferably at least 50 wt. %, based on the total weight of the composition.
  • compositions according to the present invention can be prepared using conventional techniques and equipment.
  • formulations comprising at least one API combined with at least one polyalkoxylated alcohol of the present invention can be obtained by solution-based methods such as co-precipitation and spray drying.
  • solution-based methods such as co-precipitation and spray drying.
  • spray drying a solution or dispersion comprising the at least one API and the at least one polyalkoxylated alcohol may be provided and sprayed into a heated gaseous drying medium to evaporate the solvent.
  • freeze-drying can be applied. Details of the spray drying process can e.g. be found in R. H. Perry, D. W. Green, J. O. Maloney eds., Perry's Chemical Engineers' Handbook, 6th edition, McGraw-Hill Book Co.
  • Co-precipitation can be carried out for instance by dissolving the at least one API and the at least one polyalkoxylated alcohol in a mutual solvent and subsequent mixing with a non-solvent or again by removing the solvent through evaporation.
  • Another possibility is to provide a first solution of the API component in a first solvent and a second solution of the polyalkoxylated alcohol component in a second solvent.
  • the first solvent and the second solvent can be selected in such a manner that the solubility of both components is sufficiently low in the mixture of the first and the second solvent.
  • the at least one API and the at least one polyalkoxylated alcohol can be co-precipitated by mixing both solutions.
  • the first solvent and the second solvent can be selected in such a manner that the solubility of both components is sufficiently high in the mixture of the first and the second solvent, and mixing of both solutions gives a clear solution of both components.
  • the same solvent can be selected for dissolution of both components. Removal of the solvent(s) provides a solid or semi-solid mixture of the components.
  • the at least one API and the one or more polyalkoxylated alcohols may be combined into a formulation by a melt process. For instance the at least one API may be dissolved in the molten polyalkoxylated alcohol or a mixture of multiple polyalkoxylated alcohols using conventional melt extrusion techniques.
  • the optional additives may be incorporated at any suitable stage of the preparation of the inventive pharmaceutical compositions such as by including them into the precursor solutions or dispersions or the feedstocks for melting, by adding them during the process used for combining the least one API and the one or more polyalkoxylated alcohols or by introducing them into the mixture obtained from this process.
  • the API and polyalkoxylated alcohol components may be present as a solid dispersion or the API may be dissolved in the phase comprising the one or more polyalkoxylated alcohols or be dispersed therein, wherein the dispersed API phase preferably exhibits a size of less than 1 ⁇ m in all dimensions, without being limited thereto.
  • compositions of the present invention as prepared by any one of these preparation processes are typically obtained in solid or semi-solid form e.g. as a solidified extrudate, a powder or mass of gel- or paste-like consistency and may thus be in particular conveniently used to provide solid or semi-solid dosage forms comprising a pharmaceutical compositions according to the present invention.
  • the solid dosage form can e.g. be a powder, a lozenge, a suppository, a tablet or a filled capsule.
  • Suitable semi-solid dosage forms can be exemplified by gels, creams, pastes and ointments.
  • Tablets comprising the pharmaceutical composition of the present invention may readily be prepared by conventional pressing of the raw powder or melt extrusion of the pharmaceutical composition and re-solidification using dies of the desired tablet size and shape.
  • one or more fillers which can be of the above-mentioned type, may be added for thickening in order to achieve the desired consistency for providing tablets.
  • Capsules filled with the pharmaceutical composition according to the present invention may be prepared using processing techniques and equipment, which is per se known from the prior art, e.g. from E. T. Cole, Advanced Drug Delivery Reviews 60 (2008), 747-756 .
  • Both capsules of the soft type and of the hard type can be used to encapsulate the inventive pharmaceutical compositions.
  • Soft capsules are typically formed and filled in one operation using a rotary die and have a shell consisting of a single piece.
  • Hard capsules are usually manufactured separately and consist of a cap and a body. The empty body may be filled with the targeted amount of the pharmaceutical composition according to the present invention e.g. in powder form or as hot extruded melt. Subsequently the cap is attached and the capsule sealed e.g. by applying a band of adhesive material at the body/cap interface or by moisturizing the contact area between body and cap, heating and setting.
  • the capsule shell material comprises typically gelatin as main constituent although alternative materials such as hydroxypropyl methylcellulose, iota carrageenan, hydroxypropyl starch, polyvinyl alcohol and starch may also be used.
  • the shell may include additional substances e.g. plasticizers such as water or glycerol, coloring agents and opacifiers.
  • the reactions are carried out in a parallel port reactor (PPR) setup containing a plate with 48 (6 x 8) small reactors 24 of which located in three separate modules were utilized.
  • PPR parallel port reactor
  • PO polyethylene oxide
  • EO ethylene oxide
  • the stock solutions of the starters are charged manually using a pipette into the glass inserts under nitrogen.
  • the amounts of the stock solutions range from 1.0 to 2.0 ml for all cells.
  • the glass inserts along with the stir paddles are loaded to the corresponding PPR wells and the reactors were sealed.
  • the cells are charged with calculated amounts of propylene oxide.
  • the temperature is increased to 150°C and reaction mixtures are stirred for 4 hours after reaching the process temperature.
  • the pressure profile indicated when the reactions were completed.
  • the cells are vented and purged with nitrogen to remove residual propylene oxide. The system is left overnight.
  • reactor modules are heated to 70°C, ethylene oxide is introduced, the temperature was increased to 150°C and the reactors were stirred for 4 hrs.
  • the pressure curves were consistent with reaction completion.
  • the mixtures are quenched with 10 wt% acetic acid in o-xylene. Then small samples were taken from each reactor for NMR analyses from which is determined the average number of PO and EO units.
  • a concentrate solution of 1 wt% difenoconazole and with no additive (Comparative 1 and 2) or either 10 wt% or 1 wt% polyalkoxylated amino alcohols is prepared. This is diluted with water such that the amount of the difenoconzole is 500 ppm and the amount of the polyalkyoxylated amino alcohol is either 500 ppm or 5000 ppm.
  • the mixtures are measured for light transmission for 25 hours using a Turbiscan TM tower.
  • ranges e.g. "at least 1 or at least 2 weight percent” and “up to 10 or 5 weight percent” can be combined as the ranges “1 to 10 weight percent”, or “1 to 5 weight percent” or “2 to 10 weight percent” or “2 to 5 weight percent”).
  • first do not denote any order, quantity, or importance, but rather are used to distinguish one element from another.
  • the terms “a” and “an” and “the” do not denote a limitation of quantity and are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. "Or” means “and/or” unless clearly stated otherwise.
  • test standards are the most recent standard in effect as of the filing date of this application, or, if priority is claimed, the filing date of the earliest priority application in which the test standard appears.
  • alkyl means a branched or straight chain, unsaturated aliphatic hydrocarbon group, e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl, and n- and s-hexyl, or a cycloalkyl, such as cyclohexyl, or alkyls including cyclic groups and straight or branched chains.
  • Alkoxy means an alkyl group that is linked via an oxygen (i.e., alkyl-O-), for example methoxy, ethoxy, and sec-butyloxy groups.
  • Aryl means an aromatic hydrocarbon group containing the specified number of carbon atoms, such as phenyl, tropone, indanyl, or naphthyl.
  • hetero means that the compound or group includes at least one ring member that is a heteroatom (e.g., 1, 2, or 3 heteroatom(s)), wherein the heteroatom(s) is each independently N, O, S, Si, or P.
  • the number of carbon atoms indicated in a group is exclusive of any substituents.
  • -CH 2 CH 2 CN is a C 2 alkyl group substituted with a nitrile.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Description

    FIELD OF THE INVENTION
  • The field of this invention is aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols.
  • BACKGROUND
  • It is often desirable to utilize certain types of active materials in aqueous solution. For example, it can be desirable to have and dispense certain pharmaceuticals in aqueous solution. As another example, it can be desirable to dispense agricultural chemicals such as pesticides and herbicides in a spray on aqueous solution. However, some of these materials are not soluble at the concentrations which provide effective dosages.
  • Various approaches have been proposed to obtain various aqueous stable agricultural chemical formulations (see e.g. U.S. 6,451,731 ; US 9,204,643 ; US20160235071 ; U.S. 7,977,278 ; US 7,407,667 ; U.S. 7,655,599 ; US 20080312290 , and WO2012/18885 ). Various approaches have also been proposed for solubilizing pharmaceutical actives (See e.g. U.S. 9,592,294 ; U.S. 7,776,360 ; Novel Excipient Solubilizers for Poorly Soluble Drugs, Kalantar et. al. Controlled Release Society, July 13-16, 2017).
  • WO2014/080190 discloses an agrochemical formulation comprising an agrochemical active and an esterified or etherified polyol alkoxylate as a penetrant.
  • US2012/021914 discloses suspension concentrates of a plant protective agent comprising alcohol alkylate and cyclodextrin.
  • WO01/94001 discloses microcapsules having an encapsulated material therein where the shell comprises a polymer having a surface modifying compound capable of reacting with isocyanate.
  • US2008/312290 discloses an oil based suspension concentrate of solid agrochemical active substance.
  • US2015/374823 discloses alkoxylated alcohols having the formula R-O-(AO)-H as excipient in pharmaceutical compositions.
  • JP2009-108176 discloses a thickener composition for a liquid detergent comprising at least one of a non-ionic surfactant A and a nonionic surfactant B in the molar ratios of A:B of 100:0 to 80:20.
  • US2016/289590 discloses a composition for use as a lubricant in a mechanical device, which composition comprises a base oil and a dispersant, the base oil comprising a polyalkylene glycol and the dispersant being an epoxy amine alkoxylate.
  • Nevertheless, a need remains for effective means of controlling precipitation of poorly water soluble biologically active compounds.
  • SUMMARY OF THE INVENTION
  • Disclosed herein is the use of polyalkoxylyated amino alcohols to enhance solubility of active ingredients that are poorly soluble in water or aqueous media. Specifically, disclosed is a composition comprising a biologically active compound that is insoluble or poorly soluble in water and a polyalkoxylated amino alcohol of the formula
    Figure imgb0001
    where R1, R2, R3, and R4 are independently selected from alkyl, alkenyl, aryl, aralkyl, or heterocyclic groups having 1 - 25 carbons, R5 is a divalent alkyl, alkenyl, aryl, aralkyl, or heterocyclic group having 4-25 carbons, and where each AO is a polyoxyalkylene chain having oxypropylene (PO) groups and oxyethylene (EO) groups, where m is the average number of PO groups per AO group and n is the average number of EO groups per AO group, and m is at least 1, n is at least 2, and m+n is at least 20 and no more than 400, wherein the composition is solid or comprises water.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Disclosed herein is the use of polyalkoxylyated amino alcohols to enhance processability or efficacy of water insoluble or poorly soluble biologically active compounds. Biologically active compounds are compounds which have a negative or positive impact on a living organism by interacting chemically with a living organism. Biologically active compounds include pharmaceutical actives (also referred to as active pharmaceutical ingredients or APIs) which are any substance for application in a therapeutic, diagnostic or prophylactic medical treatment of the human or animal body and (e.g. drugs) or agricultural active ingredients which are a chemical used in agriculture, horticulture and pest management for protection of crops, plants, structures, animals and humans against unwanted organisms such as fungal and bacterial plant pathogens, weeds, insects, mites, algae, nematodes and the like. Specifically, active ingredients used for these purposes include fungicides, bactericides, herbicides, insecticides, miticides, algaecides, nematocides and fumigants. The term "agricultural active ingredient" also includes insect repellants and attractants and pheromones, modifiers of plant physiology or structure, zoospore attractants and herbicide safeners.
  • As used herein biologically active compounds are considered poorly soluble if they precipitate or crystallize at concentrations at which the use is desired. For example, if a compound is most useful at concentrations or dosages of 50 mg/L but significant precipitation occurs at 20 mg/L that compound would be considered poorly soluble. Thus, the biologically active compound can have a solubility in water or aqueous medium of up to 1000, up to 700, up to 500, up to 300, up to 200, up to 100, up to 50, up to 40, up to 30, up to 20 or up to 10 parts per million. In the alternative, the biologically active compound can have a solubility in aqueous medium or water of up to 50, or up to 20 or up to 10 or up to 1 mg/L. The solubility of the biological active in an aqueous medium can be determined quantitatively e.g. by turbidity as shown in the examples below or by high pressure liquid chromatography. In the latter method for example, a solid biological active (potentially with solid excipients) is placed in an aqueous medium, after stirring for a period of time a sample would be injected into an HPLC system with an appropriate column and the area at the expected retention time based on a control sample of the active at a known concentration is evaluated.
  • The polyalkoxylated amino alcohol has the formula
    Figure imgb0002
    where R1, R2, R3, and R4 can be independently selected from alkyls of from 1 or from 2 or from 3 or from 4 to 25 or to 15 to 13 or to 12 or to 10 carbon atoms, alkenyls of from 2 or from 3 or from 4 to 25 or to 15 or to 13 or to 12 to 10 carbon atoms, aryls of 6 to 24 or to 12 carbon atoms, aralkyls of 7 to 25 or to 12 carbon atoms, or heterocyclic groups having 1 - 25 carbons, R5 can be a divalent alkyl from 4 to 25 or to 15 to 13 or to 12 or to 10 carbon atoms, alkenyl from 4 to 25 or to 15 to 13 or to 12 or to 10 carbon atoms, aryl of 6 to 24 or to 12 carbon atoms, aralkyl 7 to 25 or to 12 carbon atoms, or heterocyclic group having 4-25 carbons, and where each AO is a polyoxyalkylene chain having oxypropylene (PO) groups (e.g. -(C3H6)-O-) and oxyethylene (EO) groups (e.g. -C2H4O-). The number of PO groups in each AO group may be the same or different. The number of EO groups in each AO group may be the same or different. "m" is the average number of PO groups per AO group. "n" is the average number of EO groups per AO group. "m" is at least 1, "n" is at least 2, and m+n is at least 20 and no more than 400. R1, R2, R3, and R4 can be independently in each occurrence alkyl groups. For example, R1, R2, R3, and R4 can be butyl or ethylhexyl groups. R1, R2, R3, and R4 can be independently in each occurrence aryl groups, aralkyl groups. R5 can be a divalent group comprising 1 or 2 aromatic rings such as a diphenyl, diphenylmethane, diphenylethane, or the like and having from 6 to 25 or to 20 or to 18 carbon atoms (i.e., 6-25 or 6-20 or 6-18 carbon atoms). For example, R5 with the adjacent oxygens can be derivative of bisphenol A. Alternatively, R5 can be an aliphatic group having linear groups or cyclic groups or a combination of linear and cyclic groups and having from 3 or from 4 to 20 or to 18 or to 15 carbon atoms. For example, R5 can be 2,2-isopropylidenediphenylene, 2,2-isopropylidenedicyclohexylidene or 1,4-butylene.
  • The AO can be blocky in that it can have an EO rich block and a PO rich block. By EO rich block is meant that more than 50, more than 55, more than 60, more than 65, more than 70, more than 75, more than 80, more than 85, more than 90 or more than 95% of the groups in the block are EO groups. EO rich blocks are helpful in ensuring good water solubility. By PO rich block is meant that more than 50, more than 55, more than 60, more than 65, more than 70, more than 75, more than 80, more than 85, more than 90 or more than 95 of the groups in the block are PO groups. Alternatively, the AO group can be a block copolymer having separate EO blocks and PO blocks.
  • In determining "m" and "n" (e.g. by NMR) one can determine the total number of PO groups/molecule and EO groups/molecule. Then one can divide by the number of AO groups per molecule to get the averages which are "m" and "n". The minimum value of m can be 1, 2, 3, 4, 5, 7, 10, 12, 15, 18 or 20. The maximum value of m can be 100, 90, 80, 70, 60, or 50. For example, m could be from 1 to 100, 1 to 90, or 5 to 90. The minimum value of n can be 2, 3, 4, 5, 10, 15, 20, 25, 30, or 40. The maximum value of n can be 150, 130, 110, 100, 90, 80, or 70. m/n is preferably <1. m+n has a minimum value of 20, and can have a minimum value of 30, 40 or 50; m+n has a maximum value of 400, and can have a maximum value of 350, 300, 250, 200, or 150.
  • The biological active (e.g. agricultural active) and polyalkoxylated amino alcohol can be present in weight ratios in the range from 10:1 or from 5:1 or from 1: 1or from 1:2 to 1:100, or to 1:50, or to 1:20, or to 1:10, or to 1:5. The mole ratio of biological active to polyalkoxylated amino alcohol can be from 1:1 or from 1:2 to 1:20 or to 1:10.
  • The composition can be a liquid comprising the biological active and the polyalkoxylated amino alcohol in an aqueous medium. In that situation, the concentration of the combination of the biological active and the polyalkoxylated amino alcohol is at least 10 or at least 50 or at least 100 or at least 200 parts per million (ppm) by weight and is no more than 10 or no more than 5 or no more than 1 parts per hundred (pph) by weight.
  • In the agricultural space, the use of the polyalkoxylated amino alcohol can assist in the use of poorly water soluble agricultural active ingredients, for example, in spray applications on agricultural fields, orchards or the like. For example, the use of the polyalkoxylated amino alcohol can inhibit flash precipitation that would occur if a solvent based formulation is diluted with water or can enhance solubility of solid actives. The use of the polyalkoxylated amino alcohol may provide one or more of the following benefits, for example, 1) extended stability of aqueous agricultural active systems compared to systems that do not contain the polyalkoxylated amino alcohols; 2) produce a controlled precipitation of the agricultural active ingredient generating a controlled fine particle size distribution; 3) produce finer agricultural active ingredient particles, droplets, or precipitates in aqueous systems that do not plug nozzles and present slower settling rates compared to systems that do not contain the polyalkoxylated amino alcohols; and/or 4) hinder and/or delay the formation of large precipitates that generate problems for spray applications. In addition, the enhanced solubility could enhance efficacy if for example the mode of action includes uptake of the agricultural active ingredient by the plant or animal which uptake is enhanced by higher concentration of the active in solution or if more uniform distribution is required than is attainable by particulates.
  • Examples of insecticides include antibiotic insecticides such as allosamidin and thuringensin, macrocyclic lactone insecticides such as spinosad, spinetoram and 21-butenyl spinosyns; avermectin insecticides such as abamectin, doramectin, emamectin, eprinomectin, ivermectin and selamectin; milbemycin insecticides such as lepimectin, milbemectin, milbemycin oxime and moxidectin; botanical insecticides such as anabasine, azadirachtin, d-limonene, nicotine, pyrethrins, cinerins, cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II, quassia, rotenone, ryania and sabadilla; carbamate insecticides such as bendiocarb and carbaryl; benzofuranyl methylcarbamate insecticides such as benfuracarb, carbofuran, carbosulfan, decarbofuran and furathiocarb; dimethylcarbamate insecticides dimitan,dimetilan, hyquincarb and pirimicarb; oxime carbamate insecticides such as alanycarb,aldicarb, aldoxycarb, butocarboxim, butoxycarboxim, methomyl, nitrilacarb, oxamyl,tazimcarb, thiocarboxime, thiodicarb and thiofanox; phenyl methylcarbamate insecticides such as allyxycarb, aminocarb, bufencarb, butacarb, carbanolate, cloethocarb, dicresyl, dioxacarb, EMPC, ethiofencarb, fenethacarb, fenobucarb, isoprocarb, methiocarb, metolcarb, mexacarbate, promacyl, promecarb, propoxur, trimethacarb, XMC and xylylcarb; dinitrophenol insecticides such as dinex, dinoprop, dinosam and DNOC; fluorine insecticides such as barium hexafluorosilicate, cryolite, sodium fluoride, sodium hexafluoro silicate and sulfluramid; formamidine insecticides such as amitraz, chlordimeform, formetanate and formparanate; fumigant insecticides such as acrylonitrile, carbon disulfide, carbon tetrachloride, chloroform, chloropicrin, para-dichlorobenzene, 1,2-dichloropropane, ethyl formate, ethylene dibromide, ethylene dichloride, ethylene oxide, hydrogen cyanide, iodomethane, methyl bromide, methylchloroform, methylene chloride, naphthalene, phosphine, sulfuryl fluoride and tetrachloroethane; inorganic insecticides such as borax, calcium polysulfide, copper oleate, mercurous chloride, potassium thiocyanate and sodium thiocyanate; chitin synthesis inhibitors such as bistrifluron, buprofezin, chlorfluazuron, cyromazine, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, penfluron, teflubenzuron and triflumuron; juvenile hormone mimics such as epofenonane, fenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen and triprene; juvenile hormones such as juvenile hormone I, juvenile hormone II and juvenile hormone III; moulting hormone agonists such as chromafenozide, halofenozide, methoxyfenozide and tebufenozide; moulting hormones such as a-ecdysone and ecdysterone; moulting inhibitors such as diofenolan; precocenes such as precocene I, precocene II and precocene III; unclassified insect growth regulators such as dicyclanil; nereistoxin analogue insecticides such as bensultap, cartap, thiocyclam and thiosultap; nicotinoid insecticides such as flonicamid; nitroguanidine insecticides such as clothianidin, dinotefuran, imidacloprid and thiamethoxam; nitromethylene insecticides such as nitenpyram and nithiazine; pyridylmethylamine insecticides such as acetamiprid, imidacloprid, nitenpyram and thiacloprid; organochlorine insecticides such as bromo-DDT, camphechlor, DDT, pp'-DDT, ethyl-DDD, HCH, gamma-HCH, lindane, methoxychlor, pentachlorophenol and TDE; cyclodiene insecticides such as aldrin, bromocyclen, chlorbicyclen, chlordane, chlordecone, dieldrin, dilor, endosulfan, endrin, HEOD, heptachlor, HHDN, isobenzan, isodrin, kelevan and mirex; organophosphate insecticides such as bromfenvinfos, chlorfenvinphos, crotoxyphos, dichlorvos, dicrotophos, dimethylvinphos, fospirate, heptenophos,methocrotophos, mevinphos, monocrotophos, naled, naftalofos, phosphamidon, propaphos, TEPP and tetrachlorvinphos; organothiophosphate insecticides such as dioxabenzofos, fosmethilan and phenthoate; aliphatic organothiophosphate insecticides such as acethion, amiton, cadusafos, chlorethoxyfos, chlormephos, demephion, demephion-O, demephion-S, demeton, demeton-O, demeton-S, demeton-methyl, demeton-O-methyl, demeton-S-methyl, demeton-S-methylsulphon, disulfoton, ethion, ethoprophos, IPSP, isothioate, malathion, methacrifos, oxydemetonmethyl, oxydeprofos, oxydisulfoton, phorate, sulfotep, terbufos and thiometon; aliphatic amide organothiophosphate insecticides such as amidithion, cyanthoate, dimethoate, ethoatemethyl, formothion, mecarbam, omethoate, prothoate, sophamide and vamidothion; oxime organothiophosphate insecticides such as chlorphoxim, phoxim and phoxim-methyl; heterocyclic organothiophosphate insecticides such as azamethiphos, coumaphos, coumithoate, dioxathion, endothion, menazon, morphothion, phosalone, pyraclofos, pyridaphenthion and quinothion; benzothiopyran organothiophosphate; insecticides such as dithicrofos and thicrofos; benzotriazine organothiophosphate insecticides such as azinphosethyl and azinphos-methyl; isoindole organothiophosphate insecticides such as dialifos and phosmet; isoxazole organothiophosphate insecticides such as isoxathion and zolaprofos; pyrazolopyrimidine organothiophosphate insecticides such as chlorprazophos and pyrazophos; pyridine organothiophosphate insecticides such as chlorpyrifos and chlorpyrifosmethyl; pyrimidine organothiophosphate insecticides such as butathiofos, diazinon, etrimfos, lirimfos, pirimiphos-ethyl, pirimiphos-methyl, primidophos, pyrimitate and tebupirimfos; quinoxaline organothiophosphate insecticides such as quinalphos and quinalphos-methyl; thiadiazole organothiophosphate insecticides such as athidathion, lythidathion, methidathion and prothidathion; triazole organothiophosphate insecticides such as isazofos and triazophos; phenyl organothiophosphate insecticides such as azothoate, bromophos, bromophos-ethyl, carbophenothion, chlorthiophos, cyanophos, cythioate, dicapthon, dichlofenthion, etaphos, famphur, fenchlorphos, fenitrothion, fensulfothion, fenthion, fenthion-ethyl, heterophos, jodfenphos, mesulfenfos, parathion, parathion-methyl, phenkapton, phosnichlor, profenofos, prothiofos, sulprofos, temephos, trichlormetaphos-3 and trifenofos; phosphonate insecticides such as butonate and trichlorfon; phosphonothioate insecticides such as imicyafos and mecarphon; phenyl ethylphosphonothioate insecticides such as fonofos and trichloronat; phenyl phenylphosphonothioate insecticides such as cyanofenphos, EPN and leptophos; phosphoramidate insecticides such as crufomate, fenamiphos, fosthietan, mephosfolan,phosfolan and pirimetaphos; phosphoramidothioate insecticides such as acephate, isocarbophos, isofenphos, methamidophos and propetamphos; phosphorodiamide insecticides such as dimefox, mazidox, mipafox and schradan; oxadiazine insecticides such as indoxacarb; phthalimide insecticides such as dialifos, phosmet and tetramethrin; pyrazole insecticides such as acetoprole, ethiprole, fipronil, pyrafluprole, pyriprole, tebufenpyrad, tolfenpyrad and vaniliprole; pyrethroid ester insecticides such as acrinathrin, allethrin, bioallethrin, barthrin, bifenthrin, ioethanomethrin, cyclethrin, cycloprothrin, cyfluthrin, betacyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alphacypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin, deltamethrin, dimefluthrin, dimethrin, empenthrin, fenfluthrin, fenpirithrin, fenpropathrin, fenvalerate, esfenvalerate, flucythrinate, fluvalinate, tau-fluvalinate, furethrin, imiprothrin, metofluthrin, permethrin, biopermethrin, transpermethrin, phenothrin, prallethrin, profluthrin, pyresmethrin, resmethrin, bioresmethrin, cismethrin, tefluthrin, terallethrin, tetramethrin, tralomethrin and transfluthrin; pyrethroid ether insecticides such as etofenprox, flufenprox, halfenprox, protrifenbute and silafluofen; pyrimidinamine insecticides such as flufenerim and pyrimidifen; pyrrole insecticides such as chlorfenapyr; ryanodine receptor insecticides such as flubendiamide, chlorantraniliprole (rynaxypyr) and cyantranilipole; tetronic acid insecticides such as spirodiclofen, spiromesifen and spirotetramat; thiourea insecticides such as diafenthiuron; urea insecticides such as flucofuron and sulcofuron; sulfoximine insecticides such as sulfoxaflor and unclassified insecticides such as closantel, crotamiton, EXD, fenazaflor, fenazaquin, fenoxacrim, fenpyroximate, flubendiamide, hydramethylnon, isoprothiolane, malonoben, metaflumizone, metoxadiazone, nifluridide, pyridaben, pyridalyl, pyrifluquinazon, rafoxanide, triarathene and triazamate. Insecticides can be chosen based on water solubilities published in compendia such as The Pesticide Manual Fourteenth Edition, (ISBN 1-901396-14-2).
  • Examples of fungicides include ametoctradin, amisulbrom 2-(thiocyanatomethylthio)-benzothiazole, 2-phenylphenol, 8-hydroxyquinoline sulfate, antimycin, azaconazole, azoxystrobin, benalaxyl, benomyl, benthiavalicarb-isopropyl, benzylaminobenzene-sulfonate (BABS) salt, bicarbonates, biphenyl, bismerthiazol, bitertanol, bixafen, blasticidin-S, borax, Bordeaux mixture, boscalid, bromuconazole, bupirimate, BYF 1047, calcium polysulfide, captafol, captan, carbendazim, carboxin, carpropamid, carvone, chloroneb, chlorothalonil, chlozolinate, copper hydroxide, copper octanoate, copper oxychloride, copper sulfate, copper sulfate (tribasic), cuprous oxide, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, coumarin, dazomet, debacarb, diammonium ethylenebis-(dithiocarbamate), dichlofluanid, dichlorophen, diclocymet, diclomezine, dichloran, diethofencarb, difenoconazole, difenzoquat ion, diflumetorim, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M,dinobuton, dinocap, meptyl dinocap, diphenylamine, dithianon, dodemorph, dodemorph acetate, dodine, dodine free base, edifenphos, enestrobin, epoxiconazole, ethaboxam, ethoxyquin, etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin, fentin acetate, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, flumorph, fluopicolide, fluopyram, fluoroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutolanil, flutriafol, fluxapyrad, folpet, formaldehyde, fosetyl, fosetyl-aluminium, uberidazole, furalaxyl, furametpyr, guazatine, guazatine acetates, GY-81, hexachlorobenzene, hexaconazole, hymexazol, imazalil, imazalil sulfate, imibenconazole, minoctadine, iminoctadine triacetate, iminoctadine tris(albesilate), ipconazole, iprobenfos, iprodione, iprovalicarb, isoprothiolane, isopyrazam, isotianil, kasugamycin, kasugamycin hydrochloride hydrate, kresoxim-methyl, mancopper, mancozeb, mandipropamid, maneb, mepanipyrim, mepronil, meptyldinocap, mercuric chloride, mercuric oxide, mercurous chloride, metalaxyl, mefenoxam, metalaxyl-M, metam, metam-ammonium, metam-potassium, metam-sodium, metconazole, methasulfocarb, methyl iodide, methyl isothiocyanate, metiram, metominostrobin, metrafenone, mildiomycin, myclobutanil, nabam, nitrothal-isopropyl, nuarimol, octhilinone, ofurace, oleic acid (fatty acids), orysastrobin, oxadixyl, oxine-copper, oxpoconazole fumarate, oxycarboxin, penflufen, pefurazoate, penconazole, pencycuron, pentachlorophenol, pentachlorophenyl laurate, penthiopyrad, phenylmercury acetate, phosphonic acid, phthalide, picoxystrobin, polyoxin B, polyoxins, polyoxorim, potassium bicarbonate, potassium hydroxyquinoline sulfate, probenazole, prochloraz, procymidone, propamocarb, propamocarb hydrochloride, propiconazole, propineb, proquinazid, prothioconazole, pyraclostrobin, pyraxostrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenox, pyrimethanil, pyriofenone, pyrometostrobin, pyroquilon, quinoclamine, quinoxyfen, quintozene, Reynoutria sachalinensis extract, sedaxane, silthiofam, simeconazole, sodium 2-phenylphenoxide, sodium bicarbonate, sodium pentachlorophenoxide, spiroxamine, sulfur, SYP-Z071, SYP-048, SYP-Z048, tar oils, tebuconazole, tebufloquin, tecnazene, tetraconazole, thiabendazole, thifluzamide, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol, triazolopyrimidine, triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumizole, triforine, triticonazole, validamycin, valiphenal, valifenate, vinclozolin, zineb, ziram, zoxamide, (RS)-N-(3,5-dichlorophenyl)-2-(methoxymethyl)-succinimide, 1,2-dichloropropane, l,3-dichloro-l,l,3,3-tetrafluoroacetone hydrate, l-chloro-2,4-dinitronaphthalene, l-chloro-2-nitropropane, 2-(2-heptadecyl-2-imidazolin-l-yl)ethanol, 2,3-dihydro-5-phenyl- 1,4-dithi-ine 1,1,4,4-tetraoxide, 2-methoxyethylmercury acetate, 2-methoxyethylmercury chloride, 2-methoxyethylmercury silicate, 3-(4-chlorophenyl)-5-methylrhodanine, 4-(2-nitroprop-l-enyl)phenyl thiocyanateme: ampropylfos,anilazine, azithiram, barium polysulfide, Bayer 32394, benodanil, benquinox, bentaluron, benzamacril; benzamacril-isobutyl, benzamorf, binapacryl, buthiobate, cadmium calcium copper zinc chromate sulfate, carbamorph, CECA, chlobenthiazone, chloraniformethan, chlorfenazole, chlorquinox, climbazole, copper bis(3-phenylsalicylate), copper zinc chromate, cufraneb, cupric hydrazinium sulfate, cuprobam, cyclafuramid, cypendazole, cyprofuram, decafentin, dichlone, dichlozoline, diclobutrazol, dimethirimol, dinocton, dinosulfon, dinoterbon, dipyrithione, ditalimfos, dodicin, drazoxolon, EBP, ESBP, etaconazole, etem, ethirim, fenaminosulf, fenapanil, fenitropan, fluotrimazole, urcarbanil, furconazole, furconazole-cis, furmecyclox, furophanate, glyodine, griseofulvin, halacrinate, Hercules 3944, hexylthiofos, ICIA0858, isopamphos, isovaledione, mebenil, mecarbinzid, metazoxolon, methfuroxam, methylmercury dicyandiamide, metsulfovax, milneb, mucochloric anhydride, myclozolin, N-3,5-dichlorophenyl-succinimide, N-3-nitrophenylitaconimide, natamycin, N-ethylmercurio-4-toluenesulfonanilide, nickel bis(dimethyldithiocarbamate), OCH, phenyl mercury dimethyldithiocarbamate, hosdiphen, prothiocarb; prothiocarb hydrochloride, pyracarbolid, pyridinitril, pyroxychlor, pyroxyfur, quinacetol; quinacetol sulfate, quinazamid, quinconazole, abenzazole, salicylanilide, SSF-109, sultropen, tecoram, thiadifluor, thicyofen, thiochlorfenphim, thiophanate, thioquinox, tioxymid, triamiphos, triarimol, triazbutil, trichlamide, UK-2A, derivatives of UK-2A such as, for example, (3S,6S,7R,8R)-8-benzyl-3-(3-(isobutyryloxymethoxy)-4-methoxypicolinamido)-6-methyl-4,9-dioxo-l,5-dioxonan-7-yl isobutyrate which has a CAS Registry Number of 328255-92-1 and will be referred to herein as 328255-92-1, urbacid, XRD-563, zarilamid, IK- 1140, and propargyl amides. Fungicides can be chosen based on water solubilities published in compendia such as The Pesticide Manual Fourteenth Edition, ISBN 1-901396-14-2.
  • Examples of herbicides include amide herbicides such as allidochlor, beflubutamid, benzadox, benzipram, bromobutide, cafenstrole, CDEA, chlorthiamid, cyprazole, dimethenamid, dimethenamid-P, diphenamid, epronaz, etnipromid, fentrazamide, flupoxam, fomesafen, halosafen, isocarbamid, isoxaben, napropamide, naptalam, pethoxamid, propyzamide, quinonamid and tebutam; anilide herbicides such as chloranocryl, cisanilide, clomeprop, cypromid, diflufenican, etobenzanid, fenasulam, flufenacet, flufenican, mefenacet, mefluidide, metamifop, monalide, naproanilide, pentanochlor, picolinafen and propanil; arylalanine herbicides such as benzoylprop, flamprop and flamprop-M; chloroacetanilide herbicides such as acetochlor, alachlor, butachlor, butenachlor, delachlor, diethatyl, dimethachlor, metazachlor, metolachlor, S-metolachlor, pretilachlor, propachlor, propisochlor, prynachlor, terbuchlor, thenylchlor and xylachlor; sulfonanilide herbicides such as benzofluor, perfluidone, pyrimisulfan and profluazol; sulfonamide herbicides such as asulam, carbasulam, fenasulam and oryzalin; antibiotic herbicides such as bilanafos; benzoic acid herbicides such as chloramben, dicamba, 2,3,6-TBA and tricamba; pyrimidinyloxybenzoic acid herbicides such as bispyribac and pyriminobac; pyrimidinylthiobenzoic acid herbicides such as pyrithiobac; phthalic acid herbicides such as chlorthal; picolinic acid herbicides such as aminopyralid, clopyralid and picloram; quinolinecarboxylic acid herbicides such as quinclorac and quinmerac; arsenical herbicides such as cacodylic acid, CMA, DSMA, hexaflurate, MAA, MAMA, MSMA, potassium arsenite and sodium arsenite; benzoylcyclohexanedione herbicides such as mesotrione, sulcotrione, tefuryltrione and tembotrione; benzofuranyl alkylsulfonate herbicides such as benfuresate and ethofumesate; carbamate herbicides such as asulam, carboxazole chlorprocarb, dichlormate, fenasulam, karbutilate and terbucarb; carbanilate herbicides such as barban, BCPC, carbasulam, carbetamide, CEPC, chlorbufam, chlorpropham, CPPC, desmedipham, phenisopham, phenmedipham, phenmedipham-ethyl, propham and swep; cyclohexene oxime herbicides such as alloxydim, butroxydim, clethodim, cloproxydim, cycloxydim, profoxydim, sethoxydim, tepraloxydim and tralkoxydim; cyclopropylisoxazole herbicides such as isoxachlortole and isoxaflutole; dicarboximide herbicides such as benzfendizone, cinidon-ethyl, flumezin, flumiclorac, flumioxazin and flumipropyn; dinitroaniline herbicides such as benfluralin, butralin, dinitramine, ethalfluralin, fluchloralin, isopropalin, methalpropalin, nitralin, oryzalin, pendimethalin, prodiamine, profluralin and trifluralin; dinitrophenol herbicides such as dinofenate, dinoprop, dinosam, dinoseb, dinoterb, DNOC, etinofen and medinoterb; diphenyl ether herbicides such as ethoxyfen; nitrophenyl ether herbicides such as acifluorfen, aclonifen, bifenox, chlomethoxyfen, chlornitrofen, etnipromid, fluorodifen, fluoroglycofen, fluoronitrofen, fomesafen, furyloxyfen, halosafen, lactofen,nitrofen, nitrofluorfen and oxyfluorfen; dithiocarbamate herbicides such as dazomet and metam; halogenated aliphatic herbicides such as alorac, chloropon, dalapon, flupropanate, hexachloroacetone, iodomethane, methyl bromide, monochloroacetic acid, SMA and TCA; imidazolinone herbicides such asimazamethabenz, imazamox, imazapic, imazapyr, imazaquin and imazethapyr; nitrile herbicides such as bromobonil, bromoxynil, chloroxynil, dichlobenil, iodobonil, ioxynil and pyraclonil; organophosphorus herbicides such as amiprofos-methyl, anilofos, bensulide, bilanafos, butamifos, 2,4-DEP, DMPA, EBEP, fosamine, glufosinate, glyphosate and piperophos; phenoxy herbicides such as bromofenoxim, clomeprop, 2,4-DEB, 2,4-DEP, difenopenten, disul, erbon, etnipromid, fenteracol and trifopsime; phenoxyacetic herbicides such as 4-CPA, 2,4-D, 3,4-DA, MCPA, MCPA-thioethyl and 2,4,5-T; phenoxybutyric herbicides such as 4-CPB, 2,4-DB, 3,4-DB, MCPB and 2,4,5-TB; phenoxypropionic herbicides such as cloprop, 4-CPP, dichlorprop, dichlorprop-P, 3,4-DP, fenoprop, mecoprop and mecoprop-P; aryloxyphenoxypropionic herbicides such as chlorazifop, clodinafop, clofop, cyhalofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, metamifop, propaquizafop, quizalofop, quizalofop-P and trifop; phenylenediamine herbicides such as dinitramine and prodiamine; pyrazolyl herbicides such as benzofenap, pyrazolynate, pyrasulfotole, pyrazoxyfen, pyroxasulfone and topramezone; pyrazolylphenyl herbicides such as fluazolate and pyraflufen; pyridazine herbicides such as credazine, pyridafol and pyridate; pyridazinone herbicides such as brompyrazon, chloridazon, dimidazon, flufenpyr, metflurazon, norflurazon, oxapyrazon and pydanon; pyridine herbicides such as aminopyralid, cliodinate, clopyralid, dithiopyr, fluroxypyr, fluroxypyr-meptyl, haloxydine, picloram, picolinafen, pyriclor, thiazopyr and triclopyr; pyrimidinediamine herbicides such as iprymidam and tioclorim; quaternary ammonium herbicides such as cyperquat, diethamquat, difenzoquat, diquat, morfamquat and paraquat; thiocarbamate herbicides such as butylate, cycloate, di-allate, EPTC, esprocarb, ethiolate, isopolinate, methiobencarb, molinate, orbencarb, pebulate, prosulfocarb, pyributicarb, sulfallate, thiobencarb, tiocarbazil, tri-allate and vernolate; thiocarbonate herbicides such as dimexano, EXD and proxan; thiourea herbicides such as methiuron; triazine herbicides such as dipropetryn, triaziflam and trihydroxytriazine; chlorotriazine herbicides such as atrazine, chlorazine, cyanazine, cyprazine, eglinazine, ipazine, mesoprazine, procyazine, proglinazine, propazine, sebuthylazine, simazine, terbuthylazine and trietazine; methoxytriazine herbicides such as atraton, methometon, prometon, secbumeton, simeton and terbumeton; methylthiotriazine herbicides such as ametryn, aziprotryne, cyanatryn, desmetryn, dimethametryn, methoprotryne, prometryn, simetryn and terbutryn; triazinone herbicides such as ametridione, amibuzin, hexazinone, isomethiozin, metamitron and metribuzin; triazole herbicides such as amitrole, cafenstrole, epronaz and flupoxam; triazolone herbicides such as amicarbazone, bencarbazone, carfentrazone, flucarbazone, propoxycarbazone, sulfentrazone and thiencarbazone-methyl; triazolopyrimidine herbicides such as cloransulam, diclosulam, florasulam, flumetsulam, metosulam, penoxsulam and pyroxsulam; uracil herbicides such as butafenacil, bromacil, flupropacil, isocil, lenacil and terbacil; 3-phenyluracils; urea herbicides such as benzthiazuron, cumyluron, cycluron, dichloralurea, diflufenzopyr, isonoruron, isouron, methabenzthiazuron, monisouron and noruron; phenylurea herbicides such as anisuron, buturon, chlorbromuron, chloreturon, chlorotoluron, chloroxuron, daimuron, difenoxuron, dimefuron, diuron, fenuron, fluometuron, fluothiuron, isoproturon, linuron, methiuron, methyldymron, metobenzuron, metobromuron, metoxuron, monolinuron, monuron, neburon, parafluron, phenobenzuron, siduron, tetrafluron and thidiazuron; pyrimidinylsulfonylurea herbicides such as amidosulfuron, azimsulfuron, bensulfuron, chlorimuron, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, mesosulfuron, nicosulfuron, orthosulfamuron, oxasulfuron, primisulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron and trifloxysulfuron; triazinylsulfonylurea herbicides such as chlorsulfuron, cinosulfuron, ethametsulfuron, iodosulfuron, metsulfuron, prosulfuron, thifensulfuron, triasulfuron, tribenuron, triflusulfuron and tritosulfuron; thiadiazolylurea herbicides such as buthiuron, ethidimuron, tebuthiuron, thiazafluron and thidiazuron; and unclassified herbicides such as acrolein, allyl alcohol, azafenidin, benazolin, bentazone, benzobicyclon, buthidazole, calcium cyanamide, cambendichlor, chlorfenac, chlorfenprop, chlorflurazole, chlorflurenol, cinmethylin, clomazone, CPMF, cresol, ortho-dichlorobenzene, dimepiperate, endothal, fluoromidine, fluridone, flurochloridone, flurtamone, fluthiacet, indanofan, methazole, methyl isothiocyanate, nipyraclofen, OCH, oxadiargyl, oxadiazon, oxaziclomefone, pentachlorophenol, pentoxazone, phenyl mercury acetate, pinoxaden, prosulfalin, pyribenzoxim, pyriftalid, quinoclamine, rhodethanil, sulglycapin, thidiazimin, tridiphane, trimeturon, tripropindan and tritac. Herbicides can be chosen based on water solubilities published in compendia such as The Pesticide Manual Fourteenth Edition, ISBN 1-901396-14-2.
  • Examples of modifiers of plant physiology or structure include ancymidol, aminoethoxyvinylglycine, 6-benzylaminopurine, carvone, chlorflurenol-methyl, chlormequat chloride, cloxyfonac, 4-CPA, cyclanilide, cytokinins, daminozide, dikegulac, ethephon, flurenol, flurprimidol, forchlorfenuron, gibberellic acids, gibberellins, inabenfide, indol-3-ylacetic acid, 4-indol-3ylbutyric acid, maleic hydrazide, mepiquat chloride, 1-methylcyclopropene, 2-(l-napthyl)acetamide, 1-napthylacetic acid, 2-napthyloxyacetic acid, nitrophenolates, paclobutrazol, Nphenylphthalamic acid, prohexadione-calcium, n-propyl dihydrojasmonate, thidiazuron, tribufos, trinexepac-ethyl, and uniconazole. Modifiers can be chosen based on water solubilities published in compendia such as The Pesticide Manual Fourteenth Edition, ISBN 1-901396-14-2.
  • Examples of herbicide safeners, include safeners such as benoxacor, benthiocarb, brassinolide, cloquintocet (mexyl), cyometrinil, cyprosulfamide, daimuron, dichlormid, dicyclonon, dimepiperate, disulfoton, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, MG 191, MON 4660, naphthalic anhydride (NA), oxabetrinil, R29148 and N-phenylsulfonylbenzoic acid amides.
  • In agricultural applications, for example, the formulation may also comprise a water miscible solvent or a solvent that is soluble in water in amounts of from 0.5 or from 1 or from 2 or from 3 or from 4 or from 5 or from 10 weight percent up to 30 or up to 20 weight percent based on total weight of water and solvent. Such solvents include glycol ethers, alcohols and ketones and they are miscible or soluble depending upon the size of the hydrocarbyl groups. Water miscible solvents include N-Methyl-2-pyrrolidone, ethylene glycol monobutyl ether, ethyl lactate, gamma-butyrolactone, propylene glycol, propylene glycol methyl ether, tetrahydrofurfuryl alcohol, 2-ethoxyethanol, dimethyl sulfoxide, 1-methoxy-2-propanol, 2-butoxyethanol, dipropylene glycol methyl ether, n-propanol, and acetone. Water soluble solvents include acetophenone, butyl lactate, cyclohexanone, propylene carbonate, methyl isobutyl ketone, n-butanol, ethylene glycol n-butyl acetate, ethylene glycol phenyl ether. Applications that are "in-can" applications frequently include such a solvent. This formulation may further include water or may be diluted with water prior to application to the intended area where herbicidal or pesticidal protection is desired. Without the presence of the polyalkoxylated amino alcohol, the dilution with water might cause the poorly soluble active to precipitate. Where solvent is present the weight ratio of solvent to water can be at least 0.1:99.9 or at least 1:99 or at least 5:95 or at least 10:90 and is no more than 99:1 or no more than 90:10 or no more than 80:20 or no more than 70:30 or no more than 60:40 or no more than 50:50.
  • The formulation could alternatively be in solid particles which are added to a tank with water prior to application to the location where the herbicide or pesticide protection is desired (e.g. field or warehouse). This embodiment could be formed by mixing the polyalkoxylated amino alcohol and pesticide together such as by dissolving in a common solvent and removing that solvent, or by spray drying together, or other such means to make a solid or semi-solid composition that can be diluted in a tank for application to a crop or field.
  • The aqueous solution including the active and the polyalkoxylated amino alcohol can be applied by spraying.
  • Other potential ingredients in an agricultural active containing formulation may be inactive or inert ingredients such as dispersants, thickening agents, stickers, filmforming agents, buffers, emulsifiers, anti-freezing agents, dyes, stabilizers, solid carriers and the like may also be incorporated into formulations. Those additional ingredients can be present, individually and/or cumulatively in amounts of less than 10 or less than 8 or less than 5 or less than 3 or less than 2 or less than 1 weight percent and 0 weight percent or at least 0.1 or at least 0.5 based on total weight of the composition.
  • In the pharmaceutical space, the use of the polyalkoxylyated amino alcohols can enable solubilization of poorly water soluble active pharmaceutical ingredients to enhance processability in manufacture of tablets and the like (e.g. by spray drying). In addition, poor aqueous solubility of pharmaceutical actives (also referred to as active pharmaceutical ingredients or APIs) can lead to lower bioavilaibility and efficacy.
  • The active pharmaceutical ingredient can generally be any substance for application in a therapeutic, diagnostic or prophylactic medical treatment of the human or animal body. The API may for instance be selected from the group of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose lowering agents, decongestants, antihistamines, antitussives, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, cholesterol-reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial agents, antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, anti-depressants, antiviral agents, anti-atherosclerotic agents, glycogen phosphorylase inhibitors, hormones, vitamins, carotinoids, antiseptic agents, cytostatics, anesthetics, neuroleptics, antimycotics, spasmolytic agents, immunoglobines, sera, thyroid therapeutic agents, antihyperkinetic agents, ophthalmic agents, neuropathy agents, metabolic regulators, muscle relaxants, anti-lipemics, hepatic therapeutic agents, coronary agents, cardiacs, regulatory peptides and enzymes and their inhibitors, sedatives, gynecological agents, gout remedies, fibrinolytics, circulationpromoting agents, diuretics, diagnostic agents, corticoids, bile duct therapeutics, antiasthmatics, anti-epileptics, antidotes, antidiabetes agents, antiallergics, analgesics, analeptics, keratolytic agents, antipyretic agents and vasodilatory agents, without being limited thereto. As disclosed herein, the use of the polyalkoxylated amino alcohols may be particularly useful for APIs which are poorly soluble in aqueous medium such as a class II drug according to the Biopharmaceutics Classification System (BCS) as these substances typically suffer from an insufficient bioavailability.
  • In addition to the polyalkoxylated amino alcohol and the API, the pharmaceutical composition can comprise further one or more physiologically compatible additives. Any conventional additives used in pharmaceutical compositions known from the prior art can be employed as long as they do not interfere with the action of the active pharmaceutical ingredient and do not adversely affect the above-described favorable effects imparted by the polyalkoxylated alcohol. If present in the inventive pharmaceutical composition, the at least one optional additive may for instance be selected from the group of fillers, pH regulators, solvents, surfactants, antioxidants, preservative agents, plasticizers, coloring agents, flavoring agents, mineral adjuvants, emollients, lubricants, perfumes and excipients other than the polyalkoxylated alcohols according to the present invention and mixtures of any of the foregoing. Suitable antioxidants can be exemplified by ascorbic acid, citric acid, vitamin E and derivatives of these compounds, as well as butylated hydroxyanisole. As plasticizer for instance mineral oils, petrolatum, lanolin, polyethylene glycol, polypropylene glycol, sorbitol, triethanol amine, benzyl benzoate, dibutyl sebacate, diethyl phthalate, glyceryl monostearate, triacetin and/or triethyl citrate could be used. Suitable solvents are e.g. water, alcohols such as ethanol, isopropyl alcohol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol and glycerol. Eligible pH regulators can be all types of physiologically acceptable acids and/or bases. Suitable surfactants can be nonionic, cationic, anionic or of the betain type. For example fatty alcohol sulfates, fatty alcohol sulfonates, fatty alcohol ether sulfates, fatty alcohol ether sulfonates, fatty alcohol alkoxylates, fatty alcohol phosphates, fatty acid sulfonates, alkyl sulfonates, alkyl polyglycosides, sorbitan esters and alkoxylated derivatives thereof, sugar fatty acid esters, fatty acid polyglycerol esters, fatty acid partial glycerides, fatty acid carboxylates, fatty alcohol succinates, quarternary ammonium compounds, alkylphenol alkoxylates or mixtures thereof could be used, without being limited thereto. Fillers that may be incorporated in the pharmaceutical composition of the present invention e.g. to modify the consistency or appearance include, without being limited thereto, for instance pigments, titania, alumina, silica, zinc oxide, magnesium stearate, silicates, alumosilicates, clay, talc, waxes and polymers e.g. cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose or hydroxypropyl methyl-cellulose. Excipients other than the polyalkoxylated alcohols according to the present invention can be exemplified for instance by the substances mentioned as excipients in the Handbook of Pharmaceutical Excipients, Third Edition, Edited by A. H. Kibbe, American Pharmaceutical Association and Pharmaceutical Press (2000), WO 00/76482 and Tables 3-5 in E. T. Cole et al., Advanced Drug Delivery Reviews 60 (2008), 747-756.
  • The composition can comprise the at least one active pharmaceutical ingredient and the at least one polyalkoxylated amino alcohol together in a combined amount corresponding to 1 to 100 wt. %, preferably at least 10 wt. %, more preferably at least 50 wt. % based on the total weight of the composition. The remainder of the pharmaceutical composition may then comprise physiologically compatible additives, if any. Such additives may thus e.g. comprise 0 to 99 wt. %, preferably 0 to 90 wt. % or 0 to 50 wt. % based on the total weight of the pharmaceutical composition. The relative amount of the at least one active pharmaceutical ingredient and the at least one polyalkoxylated alcohol can be in a weight ratio in the range from 10:1 to 1:100 of active pharmaceutical ingredient(s):the polyalkoxylated alcohol, preferably from 5:1 to 1:10, more preferably from 1: 1 to 1:3. The at least one polyalkoxylated alcohol can be present in the pharmaceutical composition in an amount of more than 5 wt. %, preferably at least 10 wt. %, more preferably at least 25 wt. %, most preferably at least 50 wt. %, based on the total weight of the composition.
  • The pharmaceutical compositions according to the present invention can be prepared using conventional techniques and equipment. For instance formulations comprising at least one API combined with at least one polyalkoxylated alcohol of the present invention can be obtained by solution-based methods such as co-precipitation and spray drying. For spray drying a solution or dispersion comprising the at least one API and the at least one polyalkoxylated alcohol may be provided and sprayed into a heated gaseous drying medium to evaporate the solvent. Alternatively, also freeze-drying can be applied. Details of the spray drying process can e.g. be found in R. H. Perry, D. W. Green, J. O. Maloney eds., Perry's Chemical Engineers' Handbook, 6th edition, McGraw-Hill Book Co. 1984, pages 20-57. Co-precipitation can be carried out for instance by dissolving the at least one API and the at least one polyalkoxylated alcohol in a mutual solvent and subsequent mixing with a non-solvent or again by removing the solvent through evaporation. Another possibility is to provide a first solution of the API component in a first solvent and a second solution of the polyalkoxylated alcohol component in a second solvent. The first solvent and the second solvent can be selected in such a manner that the solubility of both components is sufficiently low in the mixture of the first and the second solvent. Thus the at least one API and the at least one polyalkoxylated alcohol can be co-precipitated by mixing both solutions. In another possibility, the first solvent and the second solvent can be selected in such a manner that the solubility of both components is sufficiently high in the mixture of the first and the second solvent, and mixing of both solutions gives a clear solution of both components. Alternatively, the same solvent can be selected for dissolution of both components. Removal of the solvent(s) provides a solid or semi-solid mixture of the components. Furthermore the at least one API and the one or more polyalkoxylated alcohols may be combined into a formulation by a melt process. For instance the at least one API may be dissolved in the molten polyalkoxylated alcohol or a mixture of multiple polyalkoxylated alcohols using conventional melt extrusion techniques. The optional additives, if any, may be incorporated at any suitable stage of the preparation of the inventive pharmaceutical compositions such as by including them into the precursor solutions or dispersions or the feedstocks for melting, by adding them during the process used for combining the least one API and the one or more polyalkoxylated alcohols or by introducing them into the mixture obtained from this process. In the obtained product of the aforementioned preparation processes the API and polyalkoxylated alcohol components may be present as a solid dispersion or the API may be dissolved in the phase comprising the one or more polyalkoxylated alcohols or be dispersed therein, wherein the dispersed API phase preferably exhibits a size of less than 1 µm in all dimensions, without being limited thereto. The pharmaceutical compositions of the present invention as prepared by any one of these preparation processes are typically obtained in solid or semi-solid form e.g. as a solidified extrudate, a powder or mass of gel- or paste-like consistency and may thus be in particular conveniently used to provide solid or semi-solid dosage forms comprising a pharmaceutical compositions according to the present invention. The solid dosage form can e.g. be a powder, a lozenge, a suppository, a tablet or a filled capsule. Suitable semi-solid dosage forms can be exemplified by gels, creams, pastes and ointments.
  • For oral administration tablets and capsules have particularly good acceptance among most patients and are thus preferably used as delivery system. Tablets comprising the pharmaceutical composition of the present invention may readily be prepared by conventional pressing of the raw powder or melt extrusion of the pharmaceutical composition and re-solidification using dies of the desired tablet size and shape. In case the as prepared composition is semi-solid one or more fillers, which can be of the above-mentioned type, may be added for thickening in order to achieve the desired consistency for providing tablets. Capsules filled with the pharmaceutical composition according to the present invention may be prepared using processing techniques and equipment, which is per se known from the prior art, e.g. from E. T. Cole, Advanced Drug Delivery Reviews 60 (2008), 747-756. Both capsules of the soft type and of the hard type can be used to encapsulate the inventive pharmaceutical compositions. Soft capsules are typically formed and filled in one operation using a rotary die and have a shell consisting of a single piece. Hard capsules are usually manufactured separately and consist of a cap and a body. The empty body may be filled with the targeted amount of the pharmaceutical composition according to the present invention e.g. in powder form or as hot extruded melt. Subsequently the cap is attached and the capsule sealed e.g. by applying a band of adhesive material at the body/cap interface or by moisturizing the contact area between body and cap, heating and setting. The capsule shell material comprises typically gelatin as main constituent although alternative materials such as hydroxypropyl methylcellulose, iota carrageenan, hydroxypropyl starch, polyvinyl alcohol and starch may also be used. The shell may include additional substances e.g. plasticizers such as water or glycerol, coloring agents and opacifiers.
  • EXAMPLES Synthesis of amino alcohol starter
  • This synthesis of amino alcohol starter BA-DGE / DBA described below is representative of the synthesis of all of the amino alcohol starters. The other starters can be synthesized according to similar procedures. To a 30 mL vial containing a cross-shaped stir bar was added bisphenol-A diglycidyl ether (D.E.R. 331 epoxy resin, 7.40 g of epoxide equivalent weight = 185 g/ mol epoxide, 40.0 millimole (mmol) epoxide) and dibutylamine (5.16 g, 40.0 mmol, 40.0 mmol N-H). The vial was capped with an inverted 14/20 septum that was secured with copper wire. A syringe needle was inserted through the septum to vent the reaction. The reaction mixture was heated at 75 °C for 30 min, 130 °C for 2 h, and 150 °C for 2 h. The product was a clear, light yellow, viscous liquid. 1H and 13C NMR analysis of the product was consistent with the structure of amino alcohol BA-DGE / DBA. The yield was quantitative.
  • Synthesis of polyalkoxylated amino alcohols.
  • The reactions are carried out in a parallel port reactor (PPR) setup containing a plate with 48 (6 x 8) small reactors 24 of which located in three separate modules were utilized. Propylene oxide (PO) and ethylene oxide (EO) are delivered via an ISCO syringe pump equipped with a robotically controlled needle and compressed gas micro-valve.
  • A glass insert along with a removable poly(ether ether ketone) (PEEK) stir paddle for each cell are dried in a vacuum oven at 125°C. The stock solutions of the starters which are listed below were prepared in o-xylene. Potassium hydride (KH) was added to each solution with stirring overnight to produce >50 mol% of the alkoxyde as shown below:
    Amount(g) o-Xylene (g) Total (g) KH (mg) KH (mmol)
    BA-DGE/DBA 2.85 3.18 6.03 100 2.5
    BA-DGE/2EHA 2.84 3.51 6.35 80 2
    h-BA-DGE/DBA 2.85 3.36 6.21 100 2.5
    BD-DGE/DBA 2.9 2.79 5.69 150 3.75
  • The stock solutions of the starters are charged manually using a pipette into the glass inserts under nitrogen. The amounts of the stock solutions range from 1.0 to 2.0 ml for all cells.
  • The glass inserts along with the stir paddles are loaded to the corresponding PPR wells and the reactors were sealed. The cells are charged with calculated amounts of propylene oxide. The temperature is increased to 150°C and reaction mixtures are stirred for 4 hours after reaching the process temperature. The pressure profile indicated when the reactions were completed. The cells are vented and purged with nitrogen to remove residual propylene oxide. The system is left overnight.
  • Next day, reactor modules are heated to 70°C, ethylene oxide is introduced, the temperature was increased to 150°C and the reactors were stirred for 4 hrs. The pressure curves were consistent with reaction completion. After cooling and venting as described above, the mixtures are quenched with 10 wt% acetic acid in o-xylene. Then small samples were taken from each reactor for NMR analyses from which is determined the average number of PO and EO units.
    Figure imgb0003
    Figure imgb0004
  • Examples 1-15 and Comparative Examples 1 and 2
  • A concentrate solution of 1 wt% difenoconazole and with no additive (Comparative 1 and 2) or either 10 wt% or 1 wt% polyalkoxylated amino alcohols is prepared. This is diluted with water such that the amount of the difenoconzole is 500 ppm and the amount of the polyalkyoxylated amino alcohol is either 500 ppm or 5000 ppm. The mixtures are measured for light transmission for 25 hours using a Turbiscan tower. The height averaged transmission over the bottom 1/3 of the solution, normalized using the height averaged from the bottom 1/3 of the control transmission (which is made up of the alkyoxylated amino alcohol and solvent (if any) and water in concentrations in the same range as when tested with the active present). Results are shown in Table 1.
  • Difenoconazole structure
  • Figure imgb0005
    Table 1: Difenoconazole Results
    Additive Time (hours)
    Example Starter Type of AO Average number of PO groups/average number of EO groups on a per molecule basis Amount of additive (ppm) 0 1 2 4 20
    1 BA-DGE / DBA block 82/151 5000 99 99 99 99 99
    2 BA-DGE / DBA block 48/63 5000 96 95 95 95 94
    3 BA-DGE / DBA block 48/63 5000 100 100 100 99 98
    4 BA-DGE / 2EHA block 105/162 5000 98 98 98 98 98
    5 BA-DGE / 2EHA block 41/66 5000 98 98 98 98 98
    6 h-BA-DGE / DBA block 55/115 5000 100 101 101 101 101
    7 h-BA-DGE / DBA block 33/50 5000 100 100 100 100 100
    8 BD-DGE / DBA block 41/69 5000 97 98 98 98 98
    9 BD-DGE / DBA block 23/36 5000 97 97 97 97 97
    10 BA-DGE / 2EHA block 105/162 500 49 19 15 12 20
    11 BA-DGE / 2EHA block 41/66 500 90 90 90 90 90
    12 h-BA-DGE / DBA block 55/115 500 79 61 54 47 35
    13 h-BA-DGE / DBA block 33/50 500 79 79 78 77 75
    14 BD-DGE / DBA block 41/69 500 70 65 64 62 56
    15 BD-DGE / DBA block 23/36 500 39 36 35 34 31
    CE1 -- -- -- -- 1 0 0 0 1
    CE2 -- -- -- -- 1 0 0 0 1
  • Examples 16-37 and Comparative 3
  • The process of for Examples 1-15 and Comparative 1 and 2 was repeated using this time pyraclostrobin instead of the Difenoconazole. The results are shown in Table 2.
  • Pyraclostrobin Structure
  • Figure imgb0006
    Table 2: Pyraclostrobin Results
    Example Additive Time (hours)
    Starter Type PO/EO Amount of additive (ppm) 0 1 2 4 20
    24 BA-DGE / 2EHA block 105/162 5000 87 92 92 92 93
    25 BA-DGE / DBA block 82/151 5000 96 96 96 96 96
    26 BA-DGE / DBA block 48/63 5000 97 97 97 96 95
    27 BD-DGE / DBA block 41/69 5000 90 93 94 94 93
    28 h-BA-DGE / DBA block 55/115 5000 83 83 86 89 92
    29 BA-DGE / 2EHA block 41/66 5000 94 95 95 95 94
    30 h-BA-DGE / DBA block 33/50 5000 96 97 97 97 97
    31 BD-DGE / DBA block 23/36 5000 85 89 89 88 85
    32 BA-DGE / 2EHA block 105/162 500 38 6 2 1 0
    33 BA-DGE / 2EHA block 41/66 500 45 11 5 2 0
    34 h-BA-DGE / DBA block 55/115 500 69 46 35 24 7
    35 h-BA-DGE / DBA block 33/50 500 84 82 81 79 71
    36 BD-DGE / DBA block 41/69 500 47 37 33 28 15
    37 BD-DGE / DBA block 23/36 500 53 25 18 12 3
    CE 3 -- -- -- -- 2 0 0 0 0
  • For ranges, stated upper and lower limits can be combined to form ranges (e.g. "at least 1 or at least 2 weight percent" and "up to 10 or 5 weight percent" can be combined as the ranges "1 to 10 weight percent", or "1 to 5 weight percent" or "2 to 10 weight percent" or "2 to 5 weight percent"). The terms "first," "second," and the like, do not denote any order, quantity, or importance, but rather are used to distinguish one element from another. The terms "a" and "an" and "the" do not denote a limitation of quantity and are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. "Or" means "and/or" unless clearly stated otherwise.
  • Unless specified to the contrary herein, all test standards are the most recent standard in effect as of the filing date of this application, or, if priority is claimed, the filing date of the earliest priority application in which the test standard appears.
  • The term "alkyl" means a branched or straight chain, unsaturated aliphatic hydrocarbon group, e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl, and n- and s-hexyl, or a cycloalkyl, such as cyclohexyl, or alkyls including cyclic groups and straight or branched chains. "Alkenyl" means a straight or branched chain, monovalent hydrocarbon group having at least one carbon-carbon double bond (e.g., ethenyl (-HC=CH2)). "Alkoxy" means an alkyl group that is linked via an oxygen (i.e., alkyl-O-), for example methoxy, ethoxy, and sec-butyloxy groups. "Aryl" means an aromatic hydrocarbon group containing the specified number of carbon atoms, such as phenyl, tropone, indanyl, or naphthyl. The prefix "hetero" means that the compound or group includes at least one ring member that is a heteroatom (e.g., 1, 2, or 3 heteroatom(s)), wherein the heteroatom(s) is each independently N, O, S, Si, or P. The number of carbon atoms indicated in a group is exclusive of any substituents. For example -CH2CH2CN is a C2 alkyl group substituted with a nitrile.

Claims (15)

  1. A composition comprising biologically active compound that is insoluble or poorly soluble in water and a polyalkoxylated amino alcohol of the formula
    Figure imgb0007
    where R1, R2, R3, and R4 are independently selected from alkyl, alkenyl, aryl, aralkyl, or heterocyclic groups having 1 - 25 carbons, R5 is a divalent alkyl, alkenyl, aryl, aralkyl, or heterocyclic group having 4-25 carbons, and where each AO is a polyoxyalkylene chain having oxypropylene (PO) and oxyethylene (EO) groups, where m is the average number of PO groups per AO group and n is the average number of the average number of EO groups per AO group, and m is at least 1, n is at least 2, and m+n is at least 20 and no more than 400
    wherein the composition is solid or comprises water.
  2. The composition of claim 1 wherein R1, R2, R3, and R4 are independently selected alkyl groups having 3-12 carbon atoms.
  3. The composition of any one of the preceding claims wherein R1, R2, R3, and R4 are butyl or 2-ethylhexyl.
  4. The composition of anyone of the preceding claims wherein R5 is 2,2-isopropylidenediphenylene, 2,2-isopropylidenedicyclohexylidene, or 1,4-butylene.
  5. The composition of any one of the preceding claims wherein m is at least 10 and n is at least 15.
  6. The composition of any one of the preceding claims wherein m/n is less than 1.
  7. The composition of any one of the preceding claims wherein m is at least 10 and n is at least 15 and m+n is less than 300.
  8. The composition of any one of the preceding claims wherein AO is a block copolymer of PO and EO.
  9. The composition of any one of the preceding claims wherein at least one AO has an EO rich block and a PO rich block.
  10. The composition of any one of the preceding claims further comprising a solvent that is at least partially miscible with water.
  11. The composition of any one of the preceding claims which is an aqueous solution.
  12. The composition of any one of the preceding claims wherein the weight ratio of the biologically active compound to the polyalkoxylated amino alcohol is in the range of 2:1 to 1:100.
  13. The composition of anyone of the preceding claims wherein the biologically active compound is an agricultural active ingredient.
  14. The composition of any one of claims 1-12 wherein the biologically active compound is an active pharmaceutical ingredient.
  15. A method comprising diluting the composition of claim 13 with water and applying it to a crop or a field to prevent pests by spraying.
EP19821400.9A 2018-12-11 2019-11-25 Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols Active EP3893846B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862777816P 2018-12-11 2018-12-11
PCT/US2019/062949 WO2020123129A1 (en) 2018-12-11 2019-11-25 Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols

Publications (2)

Publication Number Publication Date
EP3893846A1 EP3893846A1 (en) 2021-10-20
EP3893846B1 true EP3893846B1 (en) 2024-12-04

Family

ID=68916610

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19821400.9A Active EP3893846B1 (en) 2018-12-11 2019-11-25 Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols

Country Status (6)

Country Link
US (1) US12356991B2 (en)
EP (1) EP3893846B1 (en)
JP (1) JP7391962B2 (en)
CN (1) CN112996387B (en)
BR (1) BR112021008978A2 (en)
WO (1) WO2020123129A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009108176A (en) * 2007-10-30 2009-05-21 Sanyo Chem Ind Ltd Thickener composition for liquid detergent
US20160289590A1 (en) * 2013-11-14 2016-10-06 Dow Global Technologies Llc Epoxyamine alkoxylate motor oil dispersants

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
ATE254642T1 (en) 1999-07-16 2003-12-15 Basf Ag ZWITTERIONIC POLYETHERPOLYAMINE AND METHOD FOR THE PRODUCTION THEREOF
US6451731B1 (en) 1999-09-10 2002-09-17 Monsanto Company Stable concentrated pesticidal suspension
NZ522785A (en) * 2000-06-05 2004-05-28 Syngenta Ltd Novel microcapsules
DE10117993A1 (en) 2001-04-10 2002-10-17 Clariant Gmbh Pesticidal composition containing copolymer of glycerol and both di- and mono-carboxylic acids, useful for increasing biological activity, particularly of glyphosate
DE10329714A1 (en) 2003-07-02 2005-01-20 Bayer Cropscience Ag Agrochemical formulations
JP2008524393A (en) 2004-12-21 2008-07-10 バクスター・インターナショナル・インコーポレイテッド Polyalkoxysulfonate surface modifier
DE102005048539A1 (en) * 2005-10-11 2007-04-12 Bayer Cropscience Ag Suspension concentrates based on oil
EP1905302A1 (en) 2006-09-30 2008-04-02 Bayer CropScience AG Suspension concentrates
RU2010105681A (en) * 2007-07-20 2011-08-27 Басф Се (De) COMPOSITIONS CONTAINING ALCOHOL ALCOHOLS AND APPLICATION OF ALCOHOL ALCOHOLS AS AN ADJUVANT FOR THE AGROCHEMICAL SECTOR
US20120021914A1 (en) * 2008-04-24 2012-01-26 Basf Se Cyclodextrin-containing suspension concentrates, method for producing the same and their use
UA111167C2 (en) 2010-08-05 2016-04-11 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі PESTICIDIC COMPOSITIONS OF MECHANIZED PARTICLES WITH STRENGTH
CN103313764A (en) 2010-11-17 2013-09-18 陶氏环球技术有限责任公司 Process using bisphenol A aminated and alkoxylated derivative as demulsifier
PL2548437T3 (en) * 2011-07-19 2017-01-31 Arysta Lifescience Benelux Sprl Improved method for producing emulsifiable pesticide solutions
GB201220886D0 (en) 2012-11-20 2013-01-02 Croda Int Plc Penetrants for agrochemical formulations
ES2716878T3 (en) 2012-12-21 2019-06-17 Dow Agrosciences Llc Aqueous compositions of cloquintocet-mexil thermostable
US9592294B2 (en) 2013-03-20 2017-03-14 Dow Global Technologies Llc Polyalkoxylated alcohols as excipients for pharmaceutical compositions
US10537105B2 (en) 2015-02-10 2020-01-21 Upl Limited Stable aqueous compositions
KR101832380B1 (en) 2017-02-17 2018-04-04 한국화학연구원 Novel tertiary amine-based polyol and application of the same
CN108929424A (en) * 2018-06-13 2018-12-04 三晃树脂(佛山)有限公司 A kind of novel cation hydrophilic agent and its preparation, application method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009108176A (en) * 2007-10-30 2009-05-21 Sanyo Chem Ind Ltd Thickener composition for liquid detergent
US20160289590A1 (en) * 2013-11-14 2016-10-06 Dow Global Technologies Llc Epoxyamine alkoxylate motor oil dispersants

Also Published As

Publication number Publication date
WO2020123129A1 (en) 2020-06-18
US20220007645A1 (en) 2022-01-13
JP7391962B2 (en) 2023-12-05
JP2022510902A (en) 2022-01-28
BR112021008978A2 (en) 2021-08-10
EP3893846A1 (en) 2021-10-20
CN112996387B (en) 2022-11-04
US12356991B2 (en) 2025-07-15
CN112996387A (en) 2021-06-18

Similar Documents

Publication Publication Date Title
EP2317851B1 (en) Use of 5-fluorocytosine as a fungicide
AU2013259790B2 (en) Use of pro-fungicides of UK-2A for control of Black Sigatoka
CN102574831B (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
CN102946730B (en) N3-substituted-N1-sulfonyl-5-fluoropyrimidinone derivatives
DK2461678T3 (en) MESO-LARGE CAPS FOR SUPPLYING AGRICULTURAL CHEMICALS
EP3618623B1 (en) Use of an acylic picolinamide compound as a fungicide for control of phytopathogenic fungi in row crops
CA2872022A1 (en) Use of pro-fungicides of uk-2a for control of soybean rust
AU2012268377B2 (en) Oil dispersion of sulfoximines for the control of insects
HUE027390T2 (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
AU2018261338A1 (en) Use of an acyclic picolinamide compound as a fungicide for control of phytopathogenic fungi in vegetables
US12356991B2 (en) Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols
WO2018039548A1 (en) Use of pro-fungicides of uk-2a for control of rice blast
CN113163750B (en) Aqueous solutions of poorly soluble pesticides using polyalkoxylated alcohols

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210625

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221010

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 25/30 20060101ALI20240710BHEP

Ipc: A01N 25/02 20060101ALI20240710BHEP

Ipc: A01N 25/04 20060101ALI20240710BHEP

Ipc: A01N 43/56 20060101ALI20240710BHEP

Ipc: A01N 43/707 20060101ALI20240710BHEP

Ipc: A61K 47/34 20170101ALI20240710BHEP

Ipc: A61K 47/18 20170101ALI20240710BHEP

Ipc: A61K 47/08 20060101ALI20240710BHEP

Ipc: A61K 9/08 20060101AFI20240710BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240819

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019063081

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250305

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1747391

Country of ref document: AT

Kind code of ref document: T

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019063081

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241204

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251015

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250930

Year of fee payment: 7

26N No opposition filed

Effective date: 20250905

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250930

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251001

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251201

Year of fee payment: 7